Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26025959 | 0.87 | OPRK1 (0.49) | BACE1SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL19719375 | 0.86 | LTA4H (0.52) | BACE1ERAP2LNPEPOPRK1PLG | |
| SCHEMBL14140557 | 0.86 | LTA4H (0.52) | BACE1ERAP2LNPEPOPRK1PLG | |
| SCHEMBL13166473 | 0.85 | SPHK1 (0.50) | SIRT2SIRT1SIRT3 | |
| SCHEMBL26025100 | 0.84 | RUVBL1 (0.48) | SMN1; SMN2 | |
| SCHEMBL15702056 | 0.84 | SSTR3 (0.50) | SIRT2SIRT1SIRT3 | |
| SCHEMBL23286133 | 0.83 | SMN1; SMN2 (0.46) | BACE1SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL16450329 | 0.83 | SMN1; SMN2 (0.46) | BACE1SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL23253744 | 0.81 | HDAC3 (0.46) | BACE1PLGPLAUKLKB1SMN1; SMN2 | |
| SCHEMBL26024378 | 0.81 | SPHK1 (0.51) | PLGPLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | BACE1 3521/4885SIRT5 2004/4885SIRT2 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.